Filtered By:
Education: Study
Nutrition: Omega 3

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 173 results found since Jan 2013.

Fish consumption, long-chain omega-3 fatty acids intake and risk of stroke: An updated systematic review and meta-analysis
CONCLUSIONS: Both fish consumption and LC ω3-PUFAs intake were negatively associated with the risk of stroke, especially in women, which suggest that increased intake of fishery products and LC ω3-PUFAs may benefit primary prevention of stroke.PMID:33787050 | DOI:10.6133/apjcn.202103_30(1).0017
Source: Asia Pacific Journal of Clinical Nutrition - March 31, 2021 Category: Nutrition Authors: Chen Chen Hui Huang Qiu-Qin Dai Jing Ren Hong-Hua Cai Wen-Jia Hu Xiu-Juan Zhang Wang-Tao Zhong Xiang-Yong Li Source Type: research

Do Omega-3 Fatty Acids Benefit Health?
An important clinical trial of omega-3 fatty acids in patients at high risk of cardiovascular disease is published in JAMA. In the STRENGTH trial (the Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia), 13  078 patients were randomized to receive 4 g/d of a carboxylic acid formulation of omega-3 fatty acids (a combination of eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) or corn oil as a comparator. After a median follow-up of 42 months, there was no significant difference between the o mega-3 fatty acid group (6539 patients) a...
Source: JAMA - December 8, 2020 Category: General Medicine Source Type: research

Study: Fish Oil Doesn ’ t Seem To Prevent Heart Problems
This study is consistent with earlier trials. The US Food and Drug Administration approved the fish oil-based drug Vascepa for heart attack and stroke prevention in 2019. Nissen hopes the FDA will take a look at these studies and reconsider that decision. “But it’s hard to get something undone once the genie gets out of the bottle,” he said. An editorial in the journal that accompanies the study written by Dr. Gregory Curfman, assistant professor of medicine at Harvard Medical School, also suggested the FDA should require a postmarketing clinical trial of a high-dose of fish oil, such as Vascepa, vs. corn...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 16, 2020 Category: Consumer Health News Authors: CBS Boston Tags: Boston News Health Syndicated CBSN Boston CNN fish oil Source Type: news

Effects of n-3 Fatty Acid Supplements in Elderly Patients after Myocardial Infarction: A Randomized Controlled Trial.
Conclusions: We could not detect reduction in clinical events in our elderly patients with a recent AMI, treated with 1.8 g n-3 PUFAs daily for 2 years. Clinical Trial Registration: OMEMI Study; URL: https://clinicaltrials.gov Unique Identifier: NCT01841944. PMID: 33191772 [PubMed - as supplied by publisher]
Source: Circulation - November 15, 2020 Category: Cardiology Authors: Kalstad AA, Myhre PL, Laake K, Tveit SH, Schmidt EB, Smith P, Nilsen DWT, Tveit A, Fagerland MW, Solheim S, Seljeflot I, Arnesen H, OMEMI investigators Tags: Circulation Source Type: research

Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis
AbstractPurpose of ReviewOmega-3 fatty acid (O3FA) supplementation has shown conflicting evidence regarding its benefit in cardiovascular events. We performed a pairwise and network meta-analysis to elucidate the benefit of different doses of O3FA supplementation in cardiovascular prevention.Recent FindingsFourteen studies were identified providing data on 125,763 patients. A prespecified cut-off value of< 1 g per day was set for low-dose (LD) O3FA and>  1 g per day for high-dose (HD) O3FA. The efficacy outcomes of interest were total death, cardiac death, sudden cardiac death, myocardial infarction, stroke, co...
Source: Current Atherosclerosis Reports - July 15, 2020 Category: Cardiology Source Type: research

Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
Purpose of review To discuss the current evidence regarding the relationship between omega-3 fatty acid intake and atherosclerotic cardiovascular disease (ASCVD) risk. Recent findings Combined results from randomized controlled trials using low-dosage (≤1.8 g/day of ethyl esters) eicosapentaenoic acid (EPA) or EPA + docosahexaenoic acid (DHA) suggest a small benefit for reducing coronary heart disease risk. The Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) that administered 4 g/day icosapent ethyl (IPE) to individuals on statin at high or very high ASCVD risk with elevated triglyceri...
Source: Current Opinion in Cardiology - June 6, 2020 Category: Cardiology Tags: LIPIDS AND EMERGING RISK FACTORS: Edited by Dimitri P. Mikhailidis and Anthony S. Wierzbicki Source Type: research

Icosapent Ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Authors: Bazarbashi N, Miller M Abstract INTRODUCTION: Icosapent Ethyl (IPE) is a highly purified (>96%) form of eicosapentanoic acid, a marine-derived omega-3 fatty acid known to reduce serum triglyceride levels. Experimental and human studies also support anti-atherosclerotic properties of IPE including antioxidant, anti-inflammatory, endothelial and plaque stabilizing effects. In the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT)l),the addition of 4 grams IPE daily resulted in a 25% reduction in cardiovascular events beyond statins and other standard of care therapies. ...
Source: Expert Review of Cardiovascular Therapy - April 2, 2020 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Efficacy of different doses of omega-3 fatty acids on cardiovascular outcomes: rationale and design of a network meta-analysis.
CONCLUSIONS: The present network meta-analysis results will aid physicians in the decision to prescribe O3FA in patients with or at risk of cardiovascular events. In particular, it will be able to solve controversies emerged from previous randomized clinical trials and meta-analyses regarding the benefit of different doses of O3FA supplementation in the cardiovascular prevention. PMID: 32107906 [PubMed - in process]
Source: Minerva Cardioangiologica - March 1, 2020 Category: Cardiology Tags: Minerva Cardioangiol Source Type: research

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
In this interview with Dr. Lee Hooper we find out more about this new Cochrane review -Omega-3 fatty acids for the primary and secondary prevention of cardiovascular diseaseTell us about this Cochrane ReviewThere is a great deal of public belief in the cardiovascular benefits of omega-3 fats.   Intakes of long-chain omega-3 fats in the US are higher from dietary supplements than foods.  But public health advice differs across countries. The National Institute for Health and Clinical Excellence in the UK encourages people to eat oily fish intake (the major source of long-chain omega-3 f ats) but discourages supplementatio...
Source: Cochrane News and Events - February 5, 2020 Category: Information Technology Authors: Katie Abbotts Source Type: news